Eupraxia Pharmaceuticals Inc.
HealthcareNASDAQ:EPRX · NASDAQ Global Market
+$0.01 today
Vol 0.14M · Avg 0.22M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $58.7M |
| Short-term Investments | $80.6M |
| Receivables | $665.4K |
| Other Current | $2.6M |
| Total Current Assets | $142.6M |
| PP&E (Net) | $3.2M |
| Other Non-current | $62.0K |
| Total Non-current Assets | $3.2M |
| Total Assets | $145.8M |
Analysis
Selected assets total $145.8M for Latest. The largest visible component is Short-term Investments at $80.6M, about 55.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.6M +143.4% | $33.1M +127.3% | $14.6M -41.1% | $24.7M +18.4% | $20.9M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 -100.0% | $9.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $674.2K +194.6% | $228.9K +59.5% | $143.5K | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 | $0 | $0 -100.0% | $121.5K -71.7% | $429.7K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $85.1M +147.1% | $34.4M +131.0% | $14.9M -40.8% | $25.2M -17.8% | $30.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $987.1K +132.3% | $424.9K +23.7% | $343.5K -52.2% | $718.6K +22.0% | $589.1K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $64.3K -20.3% | $80.8K +1453.6% | $5.2K +54.1% | $3.4K -89.2% | $31.4K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.1M +107.9% | $505.7K +45.0% | $348.7K -51.7% | $722.0K +16.4% | $620.4K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $86.2M +146.5% | $34.9M +129.0% | $15.3M -41.1% | $25.9M -17.1% | $31.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 -100.0% | $7.8M +7181.3% | $107.5K +13.3% | $94.9K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 -100.0% | $27.4K | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 -100.0% | $1.5M +131.1% | $646.5K +2885.1% | $21.7K +332.2% | $5.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $5.6M +81.4% | $3.1M -78.7% | $14.6M +252.3% | $4.1M +82.6% | $2.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 -100.0% | $11.9M +22.9% | $9.7M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $75.9K | $0 | $0 -100.0% | $12.0M +21.9% | $9.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $5.7M +83.8% | $3.1M -78.7% | $14.6M -9.6% | $16.1M +33.3% | $12.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $195.4M +67.9% | $116.4M +66.3% | $70.0M -27.2% | $96.1M +23.8% | $77.6M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$169.6M -29.4% | -$131.0M -64.9% | -$79.4M +24.1% | -$104.6M -40.9% | -$74.3M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$2.0M +50.9% | -$4.2M -104.2% | -$2.0M +46.0% | -$3.8M -122.8% | $16.6M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 +100.0% | -$931 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | -$1.6M -1.9% | -$1.6M -57.1% | -$996.8K -27.2% | -$783.5K +6.0% | -$833.8K | $1.4B | $337.8M | $931.4M |
| Total Equity | $80.4M +152.7% | $31.8M +4639.0% | $671.9K -93.1% | $9.8M -49.0% | $19.1M | $9.1B | $7.7B | $3.3B |
| Total Debt | $154.4K +114.8% | $71.9K -99.1% | $7.9M -35.3% | $12.2M +21.8% | $10.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$80.4M -143.4% | -$33.0M -393.5% | -$6.7M +46.7% | -$12.6M -15.2% | -$10.9M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Inventiva S.A.
NASDAQ:IVA
$200.13M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does EPRX have?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $80.56M in cash and equivalents in fiscal 2025.
How much debt does EPRX carry?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $154,362.00 of total debt, with net debt of -$80,409,120.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.